Pages

Monday, January 07, 2019

CBI’s 20th Annual Patient Assistance & Access Programs – PAP 2019

CBI’s 20th Annual Patient Assistance & Access Programs – PAP 2019
March 4-6, 2019 | Baltimore, MD
www.cbinet.com/pap

During a time when copay programs and patient support are under intense scrutiny and underinsurance continues to plague many patients, PAP 2019 convenes over 450 leaders from the patient assistance and product access field (manufacturers, copay foundations, non-profits, free clinics, advocacy organization, hospitals) to prepare you for what’s ahead. Join over 50 distinguished speakers who are prepared to address the legal environment, industry best practices and policy watch-outs related to prescription access and financial assistance.

Drug Channels readers save $400 off the standard rate when they
use discount code REK226 and register prior to January 25th.*

You can download the agenda here and see in-depth coverage on critical issues, such as:
  • The Impact of Copay Accumulators on Access and Adherence
  • Legal Underpinnings of Patient Assistance and Gain Insight on OIG Oversight
  • Technology and Automation Tools that are Improving the Patient Journey and Outcomes
  • Advancements in Electronic Benefit Verification
  • Strategies for Effectively Managing Patient Data
  • Patient-Centric Support Programs to Remove Barriers and Support Adherence
    Navigating Changes and Ensuring Coverage for Medicare Patients
  • Trends and Approaches in Nursing Support Programs
Visit www.cbinet.com/pap for further details and to register. Drug Channels readers will save $400 off the standard rate they use discount code REK226 and register prior to January 25th.*

CBI will see you there!

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates, clinic/hospital rates, non-profit rates other offers. Other restrictions may apply</>.



The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

No comments:

Post a Comment